BioNTech announced that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech. As of July 1, Sean Marett will continue as a specialist advisor to the company at least until the end of the year. A new Chief Commercial Officer will be announced by the end of March 2024. Sean Marett’s responsibilities as Chief Business Officer are beeing gradually transferred to James Ryan, Ph.D., Chief Legal Officer, who will also take on the role of Chief Business Officer of BioNTech at the end of the transition phase and upon Sean Marett’s retirement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX:
- BioNTech Announces Planned Retirement of Sean Marett
- BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
- SHAREHOLDER ALERT: Potential Recovery for BioNTech SE (BNTX) Investors
- BioNTech initiated with an Outperform at BMO Capital
- BioNTech price target raised to $171 from $168 at Canaccord